MBX MBX Biosciences, Inc.

TSX
$68.57

MBX Biosciences, Inc. (MBX) is expected to report earnings on November 5, 2026, before the market open. The consensus earnings estimate is a loss of $0.76 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +3.6% since its last earnings release on August 6, 2026.

MBX Biosciences Missed Consensus Estimates
Thursday, August 6, 2026 · 8:00 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 5
Thursday · 8:00 AM ET
Earnings Whisper
-
vs ($0.76)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $67.23

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About MBX Biosciences, Inc.

MBX Biosciences Inc. is a clinical-stage biopharmaceutical company. It focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company's pipeline includes its lead product candidate MBX 2109, MBX 1416 and MBX 4291. MBX Biosciences Inc. is based in CARMEL, Ind.

Sector

Healthcare

Industry

Biotechnology